Eli Lilly and Company
LLYHealthcare Drug Manufacturers General
Eli Lilly and Company’s revenue for fiscal 2025 (year ended December 2025) was $65.2 billion, up 44.7% from fiscal 2024.
- Revenue
- +38.6%
- EPS
- +16.3%
- Free cash flow
- +21.8%
- Total debt
- +15.0%
Quarter to September 2026, against a year earlier
Follow LLY
Alert me
Eli Lilly and Company 10-Q filed Oct 29, 2026
What changed
Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Aug 5, 2026: 2 removed · 22 modified; 8 with only figures updated; 1 moved without change
-
Modified · Financial Results
Net income and earnings per share for the three
months ended June 30, 2026 increased primarily due to higher gross margin, partially offset by higher acquired IPR&D charges, asset impairment, restructuring,andother special charges, and marketing, selling, and administrative expenses. Net income and earnings per share for the sixnine months endedJuneSeptember 30, 2026 increased primarily due to higher gross margin, partially offset by higher acquired IPR&D charges, research and development expenses, and marketing, selling, and administrative expenses.